Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Science Advances|July 17, 2026
SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brainHuijie Huang, Christina Huan Shi, Wenqi Yang, et al.
Signal Transduction and Targeted Therapy|April 15, 2022
PINK1-mediated Drp1S616 phosphorylation modulates synaptic development and plasticity via promoting mitochondrial fissionQingtao Gao, Runyi Tian, Hailong Han, et al.
Biological Psychiatry|October 8, 2018
RPS23RG1 Is Required for Synaptic Integrity and Rescues Alzheimer's Disease-Associated Cognitive DeficitsDongdong Zhao, Jian Meng, Yingjun Zhao, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
The Lancet Regional Health. Western Pacific|April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b studyYongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
Cancer Pathogenesis and Therapy|July 23, 2025
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trialYuankai Shi, Minghong Bi, Qingshan Li, et al.
Signal Transduction and Targeted Therapy|January 12, 2025
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancerZhiwei Chen, Jianhua Chen, Dingzhi Huang, et al.
Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.
Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Pageof 12